Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Clinical trial NCT00390455 · COMPLETED

Trial details

NCT number: NCT00390455
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Estrogen Receptor Positive HER2 Positive Breast Carcinoma HER2/Neu Negative Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7

Start date: 2006-09-15
Primary completion: 2014-07-01
Enrollment: 295

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.